Pharma and Biotech Daily: Novartis Acquires Tourmaline for $1.4 Billion and Biogen Prepares to Release New Lupus Data
Update: 2025-09-10
Description
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, putting over $17 billion into deals this year. The biotech industry is also seeing some activity, with LB filing for a $228 million IPO to support its phase III plans. Overall, companies like Novartis and Biogen are focusing on expanding their portfolios and developing innovative treatments for various diseases.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
